Vivos Therapeutics, Inc.
VVOS
$0.80
$0.022.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.69% | -7.70% | -29.74% | -36.68% | -8.02% |
| Total Depreciation and Amortization | 15.10% | 25.49% | 72.88% | 22.92% | -1.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -305.45% | -83.92% | 7.89% | 411.29% | -58.11% |
| Change in Net Operating Assets | 244.56% | -8.27% | 304.46% | -33.54% | 82.89% |
| Cash from Operations | 8.39% | -19.09% | 7.96% | -29.12% | 29.78% |
| Capital Expenditure | -1,944.58% | 110.77% | -531.97% | 26.06% | 14.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2,004.82% | 101.41% | -4,740.98% | 26.06% | 14.06% |
| Total Debt Issued | 447.24% | -104.32% | -- | -- | -- |
| Total Debt Repaid | 35.29% | -- | -- | -- | -- |
| Issuance of Common Stock | -14.97% | 24.07% | -- | -- | -18.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | 88.41% | -- | -- | 12.38% |
| Cash from Financing | 56.89% | -75.89% | -- | -- | -19.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.54% | -163.83% | 152.58% | -7,582.35% | 91.39% |